Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Cancer Cell-Extrinsic Roles for the Androgen Receptor in Prostate Cancer

Hahn AW., Siddiqui BA., Leo J., Dondossola E., Basham KJ., Miranti CK.

Narrative Review on Systemic / IV, published in Endocrinology (2023) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Endocrinology (2023)
Reported sample size
—
Source database
Europe PMC
PMID
37192413
PMCID
PMC10413433
DOI
10.1210/endocr/bqad078
Citations
13

Abstract (original English)

Given the central role of the androgen receptor (AR) in prostate cancer cell biology, AR-targeted therapies have been the backbone of prostate cancer treatment for over 50 years. New data indicate that AR is expressed in additional cell types within the tumor microenvironment. Moreover, targeting AR for the treatment of prostate cancer has established side effects such as bone complications and an increased risk of developing cardiometabolic disease, indicating broader roles for AR. With the advent of novel technologies, such as single-cell approaches and advances in preclinical modeling, AR has been identified to have clinically significant functions in other cell types. In this mini-review, we describe new cancer cell-extrinsic roles for AR within the tumor microenvironment as well as systemic effects that collectively impact prostate cancer progression and patient outcomes.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Bone and BonesHumansProstatic NeoplasmsReceptors, AndrogenMaleAndrogen Receptor AntagonistsTumor MicroenvironmentProstatic Neoplasms, Castration-Resistant

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research